


Highlights from 2021 Small Molecule Approvals




ibrexafungerp (Brexafemme)

β -1,3-glucan synthesis inhibitor

vulvovaginal candidiasis

oral: 300 mg BID




atogepant (Qulipta)

calcitonin gene-related peptide

(CGRP) receptor antagonist

migraine

oral: up to 60 mg QD



sotorasib (Lumakras)

KRAS^{G12C} GTPase inhibitor

NSCLC

oral: 960 mg QD

**drug
hunter**

drughunter.com